These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12796050)

  • 21. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
    Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
    Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
    [No Abstract]   [Full Text] [Related]  

  • 22. Mepolizumab and eosinophil-mediated disease.
    Walsh GM
    Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mepolizumab in eosinophilic disorders.
    Abonia JP; Putnam PE
    Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
    Shrimanker R; Pavord ID
    BioDrugs; 2017 Apr; 31(2):93-103. PubMed ID: 28364396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
    Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
    J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early decreases in blood eosinophil levels with reslizumab.
    Chanez P; McDonald M; Garin M; Murphy K
    J Allergy Clin Immunol; 2019 Apr; 143(4):1653-1655. PubMed ID: 30654046
    [No Abstract]   [Full Text] [Related]  

  • 28. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
    Oppenheimer JJ; Borish L
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
    [No Abstract]   [Full Text] [Related]  

  • 29. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
    Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on biologic-based therapy in asthma.
    Walsh GM
    Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
    Brusselle G; Germinaro M; Weiss S; Zangrilli J
    Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.
    Wang FP; Xiong XF; Liu T; Li SY; Cheng DY; Mao H
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):318-330. PubMed ID: 27677499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
    Berair R; Pavord ID
    Curr Allergy Asthma Rep; 2013 Oct; 13(5):469-76. PubMed ID: 23904099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving from an asthma pipe dream to a pipeline.
    Holmes D
    Nat Rev Drug Discov; 2012 Oct; 11(10):737-8. PubMed ID: 23023668
    [No Abstract]   [Full Text] [Related]  

  • 38. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
    Conus S; Straumann A; Simon HU
    J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.